Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen in both the hospital and outpatient treatment settings. The recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) highlight the competitive nature of this segment of the antibiotics market. Further, with the recent generic availability of key anti-MRSA agents linezolid (Pfizer’s Zyvox) and daptomycin (Merck’s Cubicin), new and older brands will need to offer improvements in key areas of differentiation to gain uptake in this crowded market. Our Current Treatment content provides deep insights drawn from a survey of around 100 hospital-based infectious disease specialists regarding inpatient treatment of MRSA in the United States today, and what factors drive those treatment decisions.